Orchestra BioMed
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.7m | (<1m) | 3.5m | 2.8m | 2.9m | 3.7m | 3.9m |
| % growth | - | (114 %) | (552 %) | (22 %) | 6 % | 28 % | 4 % |
| EBITDA | (15.7m) | (21.6m) | (31.4m) | (49.8m) | (63.0m) | (71.0m) | (59.0m) |
| % EBITDA margin | (275 %) | 2764 % | (890 %) | (1803 %) | (2162 %) | (1903 %) | (1521 %) |
| Profit | (21.4m) | (23.0m) | (33.6m) | (49.1m) | (62.1m) | (66.0m) | (61.5m) |
| % profit margin | (374 %) | 2943 % | (951 %) | (1780 %) | (2131 %) | (1769 %) | (1584 %) |
| EV / revenue | - | - | - | 118.2x | 87.0x | 67.9x | 65.3x |
| EV / EBITDA | - | - | - | -6.6x | -4.0x | -3.6x | -4.3x |
| R&D budget | 13.5m | 12.9m | 21.9m | 33.8m | - | - | - |
| R&D % of revenue | 236 % | (1648 %) | 621 % | 1225 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$22.8m | Late VC | ||
| N/A | $41.0m | Late VC | |
| N/A | $34.0m | Series B | |
$110m | Series D | ||
* | $40.0m | Debt | |
* | $160m | SPAC IPO | |
| Total Funding | CAD283m | ||
Recent News about Orchestra BioMed
EditOrchestra BioMed is a biomedical innovation company focused on developing high-impact therapies for cardiovascular diseases. The company operates in the medical device market, primarily targeting patients with hypertension and other cardiovascular conditions. Its core product, BackBeat Cardiac Neuromodulation, also known as atrioventricular interval modulation (AVIM) therapy, is an investigational bioelectronic treatment designed to significantly reduce blood pressure and modulate autonomic nervous system responses. This therapy is currently not commercially approved but shows promise in clinical investigations.
Orchestra BioMed employs a partnership-enabled business model, collaborating with leading medical device companies to drive the global commercialization of its products. This strategy allows the company to leverage the established market presence and distribution networks of its partners, such as Terumo, to bring its innovative therapies to a broader patient population. Revenue is generated through strategic alliances, licensing agreements, and potential future sales of its proprietary therapies once they receive regulatory approval.
The company serves a global market, focusing on interventional cardiologists and healthcare providers who treat cardiovascular diseases. By addressing unmet medical needs with cutting-edge solutions, Orchestra BioMed aims to improve patient outcomes and establish itself as a leader in the biomedical innovation space.
Keywords: bioelectronic therapies, hypertension, cardiovascular diseases, AVIM therapy, strategic partnerships, global commercialization, medical devices, interventional cardiologists, patient outcomes, biomedical innovation.
